Abaloparatide TFA 阿巴洛肽; BA 058 TFA; BIM 44058 TFA|西域试剂

Abaloparatide TFA 阿巴洛肽; BA 058 TFA; BIM 44058 TFA,98.32%

产品编号：Bellancom-108742A| 分子式：C₁₇₆H₃₀₁N₅₆F₃O₅₁| 分子量：4074.61

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-108742A	￥1200.00	杭州北京（现货）
Bellancom-108742A	￥3500.00	杭州北京（现货）
Bellancom-108742A	￥5500.00	杭州北京（现货）
Bellancom-108742A	￥9900.00	杭州北京（现货）
Bellancom-108742A	￥16500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Abaloparatide TFA 阿巴洛肽; BA 058 TFA; BIM 44058 TFA

产品介绍

Abaloparatide TFA (BA 058 TFA) 是一种甲状旁腺激素受体 1 PTHR1 类似物。Abaloparatide TFA 也是一种选择性 PTHR1 激活剂。Abaloparatide TFA 增强 Gs/cAMP 信号和 β-arrestin 募集。Abaloparatide TFA 可增强小鼠的骨形成和皮质结构。Abaloparatide TFA 具有用于骨质疏松症研究的潜力。

生物活性

Abaloparatide TFA (BA 058 TFA) is a parathyroid hormone receptor 1 (PTHR1) analogue. Abaloparatide TFA also is a selective PTHR1 activator. Abaloparatide TFA enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide TFA enhances bone formation and cortical structure in mice. Abaloparatide TFA has the potential for the research of osteoporosis.

体外研究

Abaloparatide TFA (0-100 nM; 40 min) 增强 MC3T3-E1 细胞中的 Gs/cAMP 信号传导和 β-arrestin 募集。
Abaloparatide TFA (0-100 nM) 在 U2OS 细胞中以剂量依赖性方式有效诱导 PTHR1 内化，EC₅₀ 值为 0.8 nM。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Abaloparatide TFA (20-80 µg/kg；皮下注射；每日一次，持续 30 天) 可增强小鼠的骨形成和皮质结构。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Sprague-Dawley rats (age 22 weeks)
Dosage:	1 µg/kg, 5 µg/kg, 25 µg/kg
Administration:	Subcutaneous injection; daily; for 12 months
Result:	Increased biochemical bone formation markers, histomorphometric indices of bone formation on trabecular, endocortical, and periosteal surfaces. Induced substantial increases in trabecular bone volume and density and improvements in trabecular microarchitecture. Stimulated periosteal expansion and endocortical bone apposition at the tibial diaphysis, leading to marked increases in cortical bone volume and density. Whole-body bone mineral density (BMD) was increasing 25%.

Animal Model:	16-week-old wild-type (WT) female C57BL/6J mice
Dosage:	20-80 µg/kg
Administration:	S.c.; daily for 30 days
Result:	Efficiently expanded cortical thickness (Ct. Th) at both doses of 20 and 80 µg/kg/day by 17% and 18%, respectively, increased P1NP levels to 227% and 407% at 20 and 80 µg/kg/day, respectively.

体内研究

Abaloparatide TFA (20-80 µg/kg；皮下注射；每日一次，持续 30 天) 可增强小鼠的骨形成和皮质结构。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Sprague-Dawley rats (age 22 weeks)
Dosage:	1 µg/kg, 5 µg/kg, 25 µg/kg
Administration:	Subcutaneous injection; daily; for 12 months
Result:	Increased biochemical bone formation markers, histomorphometric indices of bone formation on trabecular, endocortical, and periosteal surfaces. Induced substantial increases in trabecular bone volume and density and improvements in trabecular microarchitecture. Stimulated periosteal expansion and endocortical bone apposition at the tibial diaphysis, leading to marked increases in cortical bone volume and density. Whole-body bone mineral density (BMD) was increasing 25%.

Animal Model:	16-week-old wild-type (WT) female C57BL/6J mice
Dosage:	20-80 µg/kg
Administration:	S.c.; daily for 30 days
Result:	Efficiently expanded cortical thickness (Ct. Th) at both doses of 20 and 80 µg/kg/day by 17% and 18%, respectively, increased P1NP levels to 227% and 407% at 20 and 80 µg/kg/day, respectively.

性状

Solid

溶解性数据

In Vitro:

H₂O : ≥ 50 mg/mL (12.27 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.2454 mL	1.2271 mL	2.4542 mL
5 mM	0.0491 mL	0.2454 mL	0.4908 mL
10 mM	0.0245 mL	0.1227 mL	0.2454 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶